CAPR News and Press, Capricor Therapeutics Inc. From 11/12/20

Capricor Therapeutics, Inc. (CAPR) Q3 2020 Earnings Conference Call November 12, 2020 04:30 pm ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - President, Chief Executive Officer and Director Steve Gould - Executive Consultant Conference Call Participants Em...

Capricor Therapeutics (CAPR): Q3 GAAP EPS of -$0.20.Revenue of $0.02M (-85.7% Y/Y) Cash, equivalents and marketable securities totaled ~$35.3M.Press Release For further details see: Capricor Therapeutics reports Q3 results

Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- - Novel Vaccine Induce d Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins - -Development of Safe, Non-toxic Ex...

Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins Capricor Scheduling Pre-IND Meeting with FDA to Discuss Clinical Strategy LOS ANGELES, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Capricor T...

LOS ANGELES, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today, that it will release...

Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI)&...

--Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based ...

Gainers: Novus Therapeutics (NASDAQ: NVUS ) +162% . More news on: Novus Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Stocks on the move, , Read more ...

LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announce...

The following slide deck was published by Capricor Therapeutics, Inc. in conjunction with this Read more ...